Hoffmann-La Roche

599 total citations
15 papers, 446 citations indexed

About

Hoffmann-La Roche is a scholar working on Oncology, Cancer Research and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Hoffmann-La Roche has authored 15 papers receiving a total of 446 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Oncology, 7 papers in Cancer Research and 4 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Hoffmann-La Roche's work include Cancer Treatment and Pharmacology (10 papers), Breast Cancer Treatment Studies (7 papers) and Cancer Diagnosis and Treatment (3 papers). Hoffmann-La Roche is often cited by papers focused on Cancer Treatment and Pharmacology (10 papers), Breast Cancer Treatment Studies (7 papers) and Cancer Diagnosis and Treatment (3 papers). Hoffmann-La Roche collaborates with scholars based in France, Belgium and Australia. Hoffmann-La Roche's co-authors include Georges Houin, Christine Chevreau, Étienne Chatelut, R. Bugat, Pierre Canal, A Boneu, A. Pujol, D. Serin, Silvana Lanzalone and Beat Thürlimann and has published in prestigious journals such as Journal of Clinical Oncology, JNCI Journal of the National Cancer Institute and Cancer Research.

In The Last Decade

Hoffmann-La Roche

15 papers receiving 423 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Hoffmann-La Roche France 8 256 132 125 113 91 15 446
T Palva Finland 8 426 1.7× 120 0.9× 179 1.4× 277 2.5× 145 1.6× 13 663
Alison L. Jones United Kingdom 10 297 1.2× 84 0.6× 266 2.1× 121 1.1× 43 0.5× 19 518
László Thurzó Hungary 14 213 0.8× 83 0.6× 228 1.8× 46 0.4× 131 1.4× 45 613
C I Li United States 6 306 1.2× 192 1.5× 333 2.7× 122 1.1× 78 0.9× 7 666
A Hacking Switzerland 8 225 0.9× 66 0.5× 215 1.7× 175 1.5× 46 0.5× 10 416
O Abe Japan 9 336 1.3× 80 0.6× 270 2.2× 258 2.3× 93 1.0× 45 736
Karen Zempolich United States 11 196 0.8× 62 0.5× 89 0.7× 114 1.0× 94 1.0× 18 635
G Gucciardo Italy 7 248 1.0× 91 0.7× 230 1.8× 282 2.5× 48 0.5× 12 550
Luca Livraghi Italy 7 296 1.2× 34 0.3× 127 1.0× 147 1.3× 62 0.7× 11 472
E. Meneghini Italy 12 220 0.9× 44 0.3× 133 1.1× 139 1.2× 55 0.6× 24 410

Countries citing papers authored by Hoffmann-La Roche

Since Specialization
Citations

This map shows the geographic impact of Hoffmann-La Roche's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Hoffmann-La Roche with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Hoffmann-La Roche more than expected).

Fields of papers citing papers by Hoffmann-La Roche

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Hoffmann-La Roche. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Hoffmann-La Roche. The network helps show where Hoffmann-La Roche may publish in the future.

Co-authorship network of co-authors of Hoffmann-La Roche

This figure shows the co-authorship network connecting the top 25 collaborators of Hoffmann-La Roche. A scholar is included among the top collaborators of Hoffmann-La Roche based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Hoffmann-La Roche. Hoffmann-La Roche is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

15 of 15 papers shown
1.
2.
Martel, P., et al.. (2009). Factors predicting the sentinel node metastases in T1 breast cancer tumor:An analysis of 1416 cases. European Journal of Surgical Oncology. 35(12). 1245–1249. 32 indexed citations
3.
Viens, Patrice, T Palangié, Jean-­Marc Ferrero, et al.. (2009). Post-Operative 5FU-Docetaxel after High-Dose of Pre-Operative Epirubicin-Cyclophosphamide for Treatment of Inflammatory Breast Cancer: Results of the FNCLCC-Pegase 07 Trial.. Cancer Research. 69(24_Supplement). 2081–2081. 2 indexed citations
4.
Rugo, HS, Hoffmann-La Roche, Kim T. Blackwell, et al.. (2009). Ixabepilone plus capecitabine vs capecitabine in patients with triple negative tumors: a pooled analysis of patients from two large phase III clinical studies.. Cancer Research. 69(2_Supplement). 3057–3057. 39 indexed citations
5.
Berton-Rigaud, Dominique, Hoffmann-La Roche, F Penault–Llorca, et al.. (2008). Benefit of neoadjuvant capecitabine + epirubicin + cyclophosphamide (CEX) versus 5-FU + epirubicin + cyclophosphamide (FEC) for operable breast cancer (BC) followed by adjuvant docetaxel (T). Journal of Clinical Oncology. 26(15_suppl). 598–598. 2 indexed citations
6.
Valero, Vicente, Hoffmann-La Roche, Tadeusz Pieńkowski, et al.. (2007). BCIRG 007: Serum HER2 levels in women with metastatic HER2-amplified breast cancer. Journal of Clinical Oncology. 25(18_suppl). 1020–1020. 5 indexed citations
7.
André, Fabrice, Kristine Broglio, Hoffmann-La Roche, et al.. (2007). Estrogen receptor expression and efficacy of docetaxel in early breast cancer: A pooled analysis of 3,490 patients included in two randomized trials. Journal of Clinical Oncology. 25(18_suppl). 537–537. 5 indexed citations
8.
9.
Fumoleau, P., Hoffmann-La Roche, Christian Dittrich, et al.. (2000). Combined results of 4 phase I and pharmacokinetic (PK) studies of E7070, a novel chloroindolyl-sulphonamide inhibiting the activation of cdk2 and cyclin E. UCL Discovery (University College London). 7 indexed citations
10.
Thürlimann, Beat, R. Paridaens, D. Serin, et al.. (1997). Third-line hormonal treatment with exemestane in postmenopausal patients with advanced breast cancer progressing on aminoglutethimide: a phase ii multicentre multinational study. European Journal of Cancer. 33(11). 1767–1773. 119 indexed citations
11.
Roche, Hoffmann-La. (1997). Acquisition d'une licence sur un composé anti-VIH. Biofutur. 1997(165). 41–41. 2 indexed citations
12.
Toulas, Christine, J. Mihura, Christine de Balincourt, et al.. (1996). Potential prognostic value in human breast cancer of cytosolic Nme1 protein detection using an original hen specific antibody. British Journal of Cancer. 73(5). 630–635. 14 indexed citations
13.
Chatelut, Étienne, Pierre Canal, Christine Chevreau, et al.. (1995). Prediction of Carboplatin Clearance From Standard Morphological and Biological Patient Characteristics. JNCI Journal of the National Cancer Institute. 87(8). 573–580. 187 indexed citations
14.
Chatelut, Étienne, Michel Lavit, Christine Chevreau, et al.. (1995). [Prediction of carboplatin clearance from morphological and biological patient characteristics].. PubMed. 82(11). 946–53. 4 indexed citations
15.
Idson, Bernard & Hoffmann-La Roche. (1978). In vivo measurement of transepidermal water loss. 17 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by T Palva Breakdown of academic impact, for papers by Alison L. Jones Breakdown of academic impact, for papers by László Thurzó Breakdown of academic impact, for papers by C I Li Breakdown of academic impact, for papers by A Hacking Breakdown of academic impact, for papers by O Abe Breakdown of academic impact, for papers by Karen Zempolich Breakdown of academic impact, for papers by G Gucciardo Breakdown of academic impact, for papers by Luca Livraghi Breakdown of academic impact, for papers by E. Meneghini
Rankless by CCL
2026